KR100366902B1 - 섭스턴스 ｐ 길항제로서 피페리디닐아미노메틸트리플루오로메틸 시클릭 에테르 화합물 - Google Patents

섭스턴스 ｐ 길항제로서 피페리디닐아미노메틸트리플루오로메틸 시클릭 에테르 화합물

Info

Publication number
KR100366902B1
KR100366902B1 KR10-2000-7005431A KR20007005431A KR100366902B1 KR 100366902 B1 KR100366902 B1 KR 100366902B1 KR 20007005431 A KR20007005431 A KR 20007005431A KR 100366902 B1 KR100366902 B1 KR 100366902B1
Authority
KR
South Korea
Prior art keywords
alkyl
disorders
halo
antagonists
substance
Prior art date
Application number
KR10-2000-7005431A
Other languages
English (en)
Inventor
쿠니오 사타케
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Application granted granted Critical
Publication of KR100366902B1 publication Critical patent/KR100366902B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR10-2000-7005431A 1997-11-19 2000-05-18 섭스턴스 ｐ 길항제로서 피페리디닐아미노메틸트리플루오로메틸 시클릭 에테르 화합물 KR100366902B1 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB9701466 1997-11-19

Publications (1)

Publication Number Publication Date
KR100366902B1 true KR100366902B1 (ko) 2003-01-09

Family

ID=11004634

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2000-7005431A KR100366902B1 (ko) 1997-11-19 2000-05-18 섭스턴스 ｐ 길항제로서 피페리디닐아미노메틸트리플루오로메틸 시클릭 에테르 화합물

Country Status (40)

Country Link
US (2) US20030208079A1 (ko)
EP (1) EP1032571B1 (ko)
JP (2) JP3394239B2 (ko)
KR (1) KR100366902B1 (ko)
CN (1) CN1173974C (ko)
AP (1) AP909A (ko)
AR (1) AR016422A1 (ko)
AT (1) ATE219078T1 (ko)
AU (1) AU734218B2 (ko)
BG (1) BG63969B1 (ko)
CA (1) CA2310627C (ko)
CO (1) CO4771153A1 (ko)
CZ (1) CZ297315B6 (ko)
DE (1) DE69806045T2 (ko)
DK (1) DK1032571T3 (ko)
DZ (1) DZ2655A1 (ko)
EA (1) EA002621B1 (ko)
ES (1) ES2177058T3 (ko)
HK (1) HK1033313A1 (ko)
HR (1) HRP20000313B1 (ko)
HU (1) HUP0101112A3 (ko)
ID (1) ID24240A (ko)
IL (1) IL135631A0 (ko)
IS (1) IS2202B (ko)
MA (1) MA26567A1 (ko)
MY (1) MY120558A (ko)
NO (2) NO20002544L (ko)
NZ (1) NZ503912A (ko)
OA (1) OA11380A (ko)
PA (1) PA8463001A1 (ko)
PE (1) PE20000021A1 (ko)
PL (1) PL193484B1 (ko)
PT (1) PT1032571E (ko)
RS (1) RS49792B (ko)
SK (1) SK283460B6 (ko)
TN (1) TNSN98210A1 (ko)
TR (1) TR200001463T2 (ko)
TW (1) TW426667B (ko)
UA (1) UA59417C2 (ko)
WO (1) WO1999025714A1 (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812662D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
GB9812617D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
EA200101050A1 (ru) * 1999-05-06 2002-04-25 Пфайзер Продактс Инк. Замещенные бензолактамные соединения
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
ATE234832T1 (de) * 1999-05-21 2003-04-15 Pfizer Prod Inc 1-trifluorotmethyl-4-hydroxy-7-piperidinyl- aminomethylchroman-derivate
AU7557000A (en) * 1999-10-07 2001-05-10 Hisamitsu Pharmaceutical Co. Inc. Piperidine derivatives
PT1095939E (pt) * 1999-10-18 2004-04-30 Pfizer Prod Inc Processo para a preparacao de eteres ciclicos de compostos com piperidinilaminometilo
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
DK1288208T3 (da) 2001-08-30 2006-10-16 Pfizer Prod Inc Fremgangsmåde til fremstilling af 2-(4-alkyl-1-piperazinyl)-benzaldehyd- og -benzylidenforbindelser ved nucleofil aromatisk substituering af 2-flourbenzaldehyd med 4-alkyl-1-peperazin i vand som oplösningsmiddel
US20040001895A1 (en) * 2002-06-17 2004-01-01 Pfizer Inc. Combination treatment for depression and anxiety
AU2003262773A1 (en) * 2002-08-27 2004-03-19 David T. Harris Amelioration of effects of cigarette smoke
US6911544B2 (en) * 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
DE102008000891A1 (de) 2008-03-31 2009-10-01 Robert Bosch Gmbh Schutzsystem für Werkzeugmaschinen
NO2729147T3 (ko) 2011-07-04 2018-02-03
CN111918647A (zh) 2018-02-26 2020-11-10 圣拉斐尔医院有限公司 用于治疗眼痛的nk-1拮抗剂
US20230134843A1 (en) 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317987D0 (en) * 1993-08-26 1993-10-13 Glaxo Group Ltd Chemical compounds
US5886011A (en) * 1995-03-27 1999-03-23 Hisamitsu Pharmaceutical Co., Inc. Piperidine derivatives as substance P antagonists
TW475930B (en) * 1995-04-24 2002-02-11 Novartis Ag Novel compound, its use and pharmaceutical composition comprising it
DE69612003T2 (de) * 1995-07-07 2001-06-21 Pfizer Substituierte benzolaktamverbindungen als substanz-p-antagonisten
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
US6329396B1 (en) * 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
ATE234832T1 (de) * 1999-05-21 2003-04-15 Pfizer Prod Inc 1-trifluorotmethyl-4-hydroxy-7-piperidinyl- aminomethylchroman-derivate
PT1095939E (pt) * 1999-10-18 2004-04-30 Pfizer Prod Inc Processo para a preparacao de eteres ciclicos de compostos com piperidinilaminometilo

Also Published As

Publication number Publication date
PL193484B1 (pl) 2007-02-28
DZ2655A1 (fr) 2003-03-22
DK1032571T3 (da) 2002-07-15
ID24240A (id) 2000-07-13
AU9454998A (en) 1999-06-07
JP2003040777A (ja) 2003-02-13
EA200000432A1 (ru) 2000-12-25
EA002621B1 (ru) 2002-06-27
NZ503912A (en) 2002-09-27
HK1033313A1 (en) 2001-08-24
PL340642A1 (en) 2001-02-12
CN1279681A (zh) 2001-01-10
MA26567A1 (fr) 2004-12-20
TR200001463T2 (tr) 2000-12-21
HUP0101112A2 (hu) 2002-05-29
HRP20000313B1 (en) 2002-04-30
IL135631A0 (en) 2001-05-20
CN1173974C (zh) 2004-11-03
SK283460B6 (sk) 2003-08-05
IS2202B (is) 2007-02-15
NO20002544D0 (no) 2000-05-18
SK7232000A3 (en) 2001-09-11
AP9801402A0 (en) 1998-12-31
CZ297315B6 (cs) 2006-11-15
ES2177058T3 (es) 2002-12-01
AR016422A1 (es) 2001-07-04
RS49792B (sr) 2008-06-05
ATE219078T1 (de) 2002-06-15
HUP0101112A3 (en) 2002-06-28
CO4771153A1 (es) 1999-04-30
CA2310627A1 (en) 1999-05-27
NO20002544L (no) 2000-07-17
TW426667B (en) 2001-03-21
UA59417C2 (uk) 2003-09-15
AU734218B2 (en) 2001-06-07
JP2001523680A (ja) 2001-11-27
CA2310627C (en) 2005-08-09
PE20000021A1 (es) 2000-02-25
US20050171354A1 (en) 2005-08-04
CZ20001834A3 (cs) 2001-07-11
NO20042879L (no) 2000-07-17
DE69806045D1 (en) 2002-07-18
WO1999025714A1 (en) 1999-05-27
US20030208079A1 (en) 2003-11-06
PT1032571E (pt) 2002-09-30
EP1032571B1 (en) 2002-06-12
HRP20000313A2 (en) 2000-12-31
TNSN98210A1 (fr) 2005-03-15
MY120558A (en) 2005-11-30
EP1032571A1 (en) 2000-09-06
PA8463001A1 (es) 2000-09-29
OA11380A (en) 2004-01-27
JP3394239B2 (ja) 2003-04-07
BG63969B1 (bg) 2003-08-29
AP909A (en) 2000-12-04
DE69806045T2 (de) 2002-11-14
BG104437A (en) 2001-02-28
YU29400A (sh) 2003-02-28
IS5470A (is) 2000-04-26

Similar Documents

Publication Publication Date Title
KR100366902B1 (ko) 섭스턴스 ｐ 길항제로서 피페리디닐아미노메틸트리플루오로메틸 시클릭 에테르 화합물
PL321019A1 (en) Novel derivatives of quinuclidin and medical composition containing such compounds
PT780375E (pt) 3-¬(benzilo substituido em 5)amino|-2-phenilpiperidinas como antagonistas da substancia p
CA2215020A1 (en) Tetrazolyl-substituted quinuclidines as substance p antagonists
DE69715208D1 (de) Anti-helicobacter pylori zusammensetzungen die 1-methylcarbapenem-derivate als wirkstoffe enthalten
CA2374643A1 (en) 1-trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives as substance p antagonists
DK0824100T3 (da) Tricykliske piperidinylaminoforbindelser som substans P-antagonister
BR9814660A (pt) compostos de éter cìclico piperidinilaminometil-trifluorometìlico como antagonista da substáncia p e composição farmacêutica
NO176608C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-piperidinylindazol-derivater
ECSP982736A (es) Compuestos de eteres ciclicos de piperidinilaminometil trifluorometilo como antagonistas de la sustancia p.
YU79401A (sh) Derivati 1-trifluorometil-4-hidroksi-7-piperidinil- aminometilhromana

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20071011

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee